Hua Lan, Wang Cong
The Second Xiangya Hospital of Central South University, People's Republic of China.
Guiyang Maternal and Child Health Hospital, People's Republic of China.
Eur J Obstet Gynecol Reprod Biol. 2023 Apr;283:43-48. doi: 10.1016/j.ejogrb.2023.01.012. Epub 2023 Jan 13.
The objective of this meta-analysis is to determine the beneficial effect of recombinant-luteinizing Hormone (r-LH) addition in women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) with gonadotropin-releasing hormone (GnRH) antagonist protocol and whether an optimal time of Recombinant-Luteinizing Hormone (r-LH) supplementation exist during the controlled of stimulation (COS). The primary outcomes are clinical Pregnancy rate and the number of oocytes retrieved. Secondary outcomes are the number of metaphase II oocytes, miscarriage rate and live birth rate. Results show that supplementation of LH generated a greater number of oocytes retrieved than patients who did not receive LH supplementation, but it did not help with other pregnancy outcomes. Furthermore, the result of the subgroup analysis revealed no significant difference in the outcomes with different LH addition times.
本荟萃分析的目的是确定在接受促性腺激素释放激素（GnRH）拮抗剂方案体外受精/卵胞浆内单精子注射（IVF/ICSI）的女性中添加重组促黄体生成素（r-LH）的有益效果，以及在控制性促排卵（COS）期间是否存在补充重组促黄体生成素（r-LH）的最佳时间。主要结局为临床妊娠率和取卵数。次要结局为MII期卵母细胞数、流产率和活产率。结果显示，补充LH组比未补充LH组获取的卵母细胞数量更多，但对其他妊娠结局无帮助。此外，亚组分析结果显示，不同LH添加时间的结局无显著差异。
